173 related articles for article (PubMed ID: 36572864)
1. Comparative epigenomics by machine learning approach for neuroblastoma.
Sugino RP; Ohira M; Mansai SP; Kamijo T
BMC Genomics; 2022 Dec; 23(1):852. PubMed ID: 36572864
[TBL] [Abstract][Full Text] [Related]
2. Predicting amplification of
Giwa A; Rossouw SC; Fatai A; Gamieldien J; Christoffels A; Bendou H
Future Oncol; 2021 Dec; 17(34):4769-4783. PubMed ID: 34751044
[TBL] [Abstract][Full Text] [Related]
3. Integrative analysis with machine learning identifies diagnostic and prognostic signatures in neuroblastoma based on differentially DNA methylated enhancers between INSS stage 4 and 4S neuroblastoma.
Li S; Mi T; Jin L; Liu Y; Zhang Z; Wang J; Wu X; Ren C; Wang Z; Kong X; Liu J; Luo J; He D
J Cancer Res Clin Oncol; 2024 Mar; 150(3):148. PubMed ID: 38512513
[TBL] [Abstract][Full Text] [Related]
4. BLM germline and somatic PKMYT1 and AHCY mutations: Genetic variations beyond MYCN and prognosis in neuroblastoma.
Novak EM; Halley NS; Gimenez TM; Rangel-Santos A; Azambuja AM; Brumatti M; Pereira PL; Vince CS; Giorgi RR; Bendit I; Cristofani LM; Odone-Filho V
Med Hypotheses; 2016 Dec; 97():22-25. PubMed ID: 27876123
[TBL] [Abstract][Full Text] [Related]
5. GSTP1 hypermethylation is associated with reduced protein expression, aggressive disease and prognosis in neuroblastoma.
Gumy-Pause F; Pardo B; Khoshbeen-Boudal M; Ansari M; Gayet-Ageron A; Sappino AP; Attiyeh EF; Ozsahin H
Genes Chromosomes Cancer; 2012 Feb; 51(2):174-85. PubMed ID: 22045684
[TBL] [Abstract][Full Text] [Related]
6. EZH2 regulates neuroblastoma cell differentiation via NTRK1 promoter epigenetic modifications.
Li Z; Takenobu H; Setyawati AN; Akita N; Haruta M; Satoh S; Shinno Y; Chikaraishi K; Mukae K; Akter J; Sugino RP; Nakazawa A; Nakagawara A; Aburatani H; Ohira M; Kamijo T
Oncogene; 2018 May; 37(20):2714-2727. PubMed ID: 29507419
[TBL] [Abstract][Full Text] [Related]
7. Transcript signatures that predict outcome and identify targetable pathways in MYCN-amplified neuroblastoma.
Hallett RM; Seong AB; Kaplan DR; Irwin MS
Mol Oncol; 2016 Nov; 10(9):1461-1472. PubMed ID: 27599694
[TBL] [Abstract][Full Text] [Related]
8. Genome-wide promoter methylation analysis in neuroblastoma identifies prognostic methylation biomarkers.
Decock A; Ongenaert M; Hoebeeck J; De Preter K; Van Peer G; Van Criekinge W; Ladenstein R; Schulte JH; Noguera R; Stallings RL; Van Damme A; Laureys G; Vermeulen J; Van Maerken T; Speleman F; Vandesompele J
Genome Biol; 2012 Oct; 13(10):R95. PubMed ID: 23034519
[TBL] [Abstract][Full Text] [Related]
9. Hypermethylation of apoptotic genes as independent prognostic factor in neuroblastoma disease.
Grau E; Martinez F; Orellana C; Canete A; Yañez Y; Oltra S; Noguera R; Hernandez M; Bermúdez JD; Castel V
Mol Carcinog; 2011 Mar; 50(3):153-62. PubMed ID: 21104989
[TBL] [Abstract][Full Text] [Related]
10. Histone-lysine methyltransferase EHMT2 is involved in proliferation, apoptosis, cell invasion, and DNA methylation of human neuroblastoma cells.
Lu Z; Tian Y; Salwen HR; Chlenski A; Godley LA; Raj JU; Yang Q
Anticancer Drugs; 2013 Jun; 24(5):484-93. PubMed ID: 23466651
[TBL] [Abstract][Full Text] [Related]
11. Co-amplification and concomitant high levels of expression of a DEAD box gene with MYCN in human neuroblastoma.
Manohar CF; Salwen HR; Brodeur GM; Cohn SL
Genes Chromosomes Cancer; 1995 Nov; 14(3):196-203. PubMed ID: 8589036
[TBL] [Abstract][Full Text] [Related]
12. Association of epigenetic inactivation of RASSF1A with poor outcome in human neuroblastoma.
Yang Q; Zage P; Kagan D; Tian Y; Seshadri R; Salwen HR; Liu S; Chlenski A; Cohn SL
Clin Cancer Res; 2004 Dec; 10(24):8493-500. PubMed ID: 15623630
[TBL] [Abstract][Full Text] [Related]
13. Genomic profile of MYCN non-amplified neuroblastoma and potential for immunotherapeutic strategies in neuroblastoma.
Lee E; Lee JW; Lee B; Park K; Shim J; Yoo KH; Koo HH; Sung KW; Park WY
BMC Med Genomics; 2020 Nov; 13(1):171. PubMed ID: 33172452
[TBL] [Abstract][Full Text] [Related]
14. Machine learning methods revealed the roles of immune-metabolism related genes in immune infiltration, stemness, and prognosis of neuroblastoma.
Mu J; Gong J; Lin P; Zhang M; Wu K
Cancer Biomark; 2023; 38(2):241-259. PubMed ID: 37545226
[TBL] [Abstract][Full Text] [Related]
15. Neuroblastoma epigenetics: from candidate gene approaches to genome-wide screenings.
Decock A; Ongenaert M; Vandesompele J; Speleman F
Epigenetics; 2011 Aug; 6(8):962-70. PubMed ID: 21725203
[TBL] [Abstract][Full Text] [Related]
16. The von Hippel-Lindau tumor suppressor gene expression level has prognostic value in neuroblastoma.
Hoebeeck J; Vandesompele J; Nilsson H; De Preter K; Van Roy N; De Smet E; Yigit N; De Paepe A; Laureys G; Påhlman S; Speleman F
Int J Cancer; 2006 Aug; 119(3):624-9. PubMed ID: 16506218
[TBL] [Abstract][Full Text] [Related]
17. Integrated machine learning-driven disulfidptosis profiling: CYFIP1 and EMILIN1 as therapeutic nodes in neuroblastoma.
Mengzhen Z; Xinwei H; Zeheng T; Nan L; Yang Y; Huirong Y; Kaisi F; Xiaoting D; Liucheng Y; Kai W
J Cancer Res Clin Oncol; 2024 Mar; 150(3):109. PubMed ID: 38427078
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic silencing of prostaglandin E receptor 2 (PTGER2) is associated with progression of neuroblastomas.
Sugino Y; Misawa A; Inoue J; Kitagawa M; Hosoi H; Sugimoto T; Imoto I; Inazawa J
Oncogene; 2007 Nov; 26(53):7401-13. PubMed ID: 17533365
[TBL] [Abstract][Full Text] [Related]
19. Valproic acid shows a potent antitumor effect with alteration of DNA methylation in neuroblastoma.
Gu S; Tian Y; Chlenski A; Salwen HR; Lu Z; Raj JU; Yang Q
Anticancer Drugs; 2012 Nov; 23(10):1054-66. PubMed ID: 22863973
[TBL] [Abstract][Full Text] [Related]
20. Epigenome-wide association study reveals CpG sites related to COG of neuroblastoma.
Zhao H; Zhou X; Sun H; Zhao D; Liu H; Huang B; Li X; Gu Y
Biosci Rep; 2020 May; 40(5):. PubMed ID: 32378698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
